🟢 ADMA Biologics is trading 22.23% up in pre-market after stronger third-quarter results and raised profit outlook

ADMA Biologics is trading at $12.81, up 22.23% in pre-market on November 5 after its third-quarter report, released after the November 4 close, raised minimum profit guidance. - Revenue was $141.1 million; ASCENIV revenue rose 31% year over year to $124.7 million, and gross margin expanded to 71%. - Management maintained 2026 revenue guidance of at least $530 million and raised minimum adjusted net income guidance to $180 million and adjusted EBITDA guidance to $275 million.